Key molecules like ATP, ADP, and adenosine, acting through purinergic receptors (P1 and P2), have been implicated in the regulation of endocrine functions, including insulin secretion, glucose ...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and ...